Weekly Round Up

Tariffs Changed the MedTech Playbook

Pharma’s $130B M&A Comeback, China’s Innovation Rise, Healthcare’s Third-Party Risk

Biopharma dealmaking is accelerating as drug innovation goes global—and China closes the gap with the U.S.

Lilly’s $3.35B China Bet, Healthcare M&A’s Bottleneck, Biotech’s New Pipeline

Plus: once-weekly insulin, $120B in China-linked licensing deals, and the risks slowing healthcare M&A.

Hospitals’ Next Margin Lever, AI’s Trust Gap, Healthcare M&A

Labor productivity takes center stage, 60% of consumers are already using AI for health, and big-ticket healthcare deals remain missing.

Europe’s Pharma Warning, Apollo’s Healthcare Play & China’s $60B Biotech Boom

Europe fights to keep biotech capital as Apollo consolidates healthcare media and China becomes a global pharma pipeline.

AI Is Moving Biotech’s Bottleneck

Biosimilars get strategic, biotech’s bottleneck shifts downstream, and life sciences faces the AI ROI test.

The Biopharma Map Is Moving

FDA Hits Fast-Forward on Clinical Trials, GSK Doubles Down on Myeloma, and Asia Takes the Biopharma Wheel

Healthcare Leaves the Hospital, Virtual Care’s $248B Run, AI’s Next Test

Care is moving outpatient, virtual care is scaling fast, and healthcare AI faces its orchestration test.

The Hospital Performance Problem No One Agrees On

Hospital leaders split on the industry’s biggest performance gap, the FDA clears a new oncology treatment, and Toscafund makes a $1B+ take private bet.

Healthcare Buyouts Are Back: $191B, Healthtech’s 2.3x Edge & Pharma’s Next Winners

Healthcare PE rebounds 52%, healthcare IT leads returns, and pharma’s growth map gets redrawn.

Gen Z’s Health Signal, Lilly’s $2.9B Bet, China PE Reawakens

Plus: GLP-1 dealmaking, China’s healthcare rebound, and the next wave of healthtech.

Pharma PE Is Still Waiting for the Floor

Healthcare dealmaking slows, AI rewrites underwriting, and investor competition keeps rising.